Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds
- PMID: 10985881
- DOI: 10.1006/gyno.2000.5861
Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds
Abstract
Objective: The literature reports conflicting studies claiming premalignant histological features in benign ovaries from women who may have hereditary predilections for ovarian carcinoma. To test the veracity of these claims, this investigation studied ovaries prophylactically removed from members of hereditary breast ovarian cancer (HBOC) syndrome families who carry BRCA1 and BRCA2 mutations and compared these with the ovaries of mutation-negative women from the same HBOC syndrome kindred.
Methods: Sixty cases of women from HBOC syndrome families who had undergone prophylactic oophorectomies and whose BRCA1 and BRCA2 mutation status had been tested were selected from our database. Thirty had tested positive for BRCA1 mutations, 3 carried BRCA2 mutations, and 27 were negative for both BRCA1 and BRCA2 germline mutations. Histologic material from each case was examined by light microscopy blinded to the mutation status. Histologic features, previously reported to be possible precursor lesions for ovarian cancer, were quantified. Data from BRCA1 and BRCA2 mutation carriers were compared with those from mutation-negative cases in the direct line of genetic inheritance from the same HBOC syndrome families.
Results: Statistical analysis found that a more frequent occurrence of ovarian surface micropapillae in 87% of mutation carriers compared with just 55% of mutation-negative cases was the only histologic feature which was significantly different between the two groups (P = 0.39). Cortical clefts tended to be deeper in the ovaries of mutation carriers, but this did not reach significance (P = 0.051). There were no other significant histologic differences between the ovaries removed from mutation carriers and those from noncarriers.
Conclusions: The results of our large and prospectively controlled, blinded study contrast with those reported from smaller, unblinded investigations. Except for the possible biological significance of surface micropapillae on ovaries from BRCA1 and BRCA2 mutation carriers, we found no histologic evidence for a genetically determined ovarian carcinoma precursor lesion.
Copyright 2000 Academic Press.
Similar articles
-
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.Gynecol Oncol. 2005 May;97(2):457-67. doi: 10.1016/j.ygyno.2005.01.039. Gynecol Oncol. 2005. PMID: 15863145
-
A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.Cas Lek Cesk. 2000 Oct 11;139(20):635-7. Cas Lek Cesk. 2000. PMID: 11192759
-
Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.Hum Mutat. 2001;17(1):74. doi: 10.1002/1098-1004(2001)17:1<74::AID-HUMU13>3.0.CO;2-I. Hum Mutat. 2001. PMID: 11139249
-
Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.J Clin Oncol. 2000 Nov 1;18(21 Suppl):100S-3S. J Clin Oncol. 2000. PMID: 11060335 Review.
-
Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.Eur J Cancer Prev. 2000 Jun;9(3):139-50. Eur J Cancer Prev. 2000. PMID: 10954253 Review.
Cited by
-
Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.Int J Mol Sci. 2011 Jan 31;12(2):1009-29. doi: 10.3390/ijms12021009. Int J Mol Sci. 2011. PMID: 21541039 Free PMC article. Review.
-
A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants.Nat Genet. 2019 May;51(5):815-823. doi: 10.1038/s41588-019-0395-x. Epub 2019 May 1. Nat Genet. 2019. PMID: 31043753 Free PMC article.
-
Identification of Tumor Microenvironment Scoring Scheme Based on Bioinformatics Analysis of Immune Cell Infiltration Pattern of Ovarian Cancer.J Oncol. 2022 Aug 30;2022:7745675. doi: 10.1155/2022/7745675. eCollection 2022. J Oncol. 2022. PMID: 36081665 Free PMC article.
-
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.Mol Oncol. 2009 Apr;3(2):97-137. doi: 10.1016/j.molonc.2009.02.004. Epub 2009 Feb 21. Mol Oncol. 2009. PMID: 19383374 Free PMC article. Review.
-
BRCA mutations in the manifestation and treatment of ovarian cancer.Oncotarget. 2017 May 30;8(57):97657-97670. doi: 10.18632/oncotarget.18280. eCollection 2017 Nov 14. Oncotarget. 2017. PMID: 29228641 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous